
Immunogenicity of replication-defective recombinant vesicular stomatitis virus expressing Middle East respiratory syndrome coronavirus spike protein in mice
- Jung-Eun Park
- 한국예방수의학회
- Journal of Preventive Veterinary Medicine
- Vol.45, No.2
- 등재여부 : KCI등재
- 2021.06
- 70 - 76 (7 pages)
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans, with a case fatality rate of approximately 35%, thus posing a considerable threat to public health. A lack of approved vaccines or antivirals currently constitutes a barrier for controlling disease outbreaks and spread. In this study, we generated a replication-defective recombinant vesicular stomatitis virus expressing the MERS-CoV spike (S) protein (VSV/MERS). Uncleaved and cleaved S proteins were detected in VSV/MERS by western blotting. And VSV/MERS specifically transduced cells expressing human dipeptidyl peptidase 4, a receptor for MERS-CoV. To investigate the immunogenicity of VSV/MERS, mice were immunized intramuscularly with VSV/MERS and alum adjuvant. MERS-CoV S-specific IgG was detected in serum samples from immunized mice. These antibodies inhibited MERS entry in vitro, suggesting a protective efficacy of VSV/MERS immunity. The data demonstrate that VSV/MERS has potent immunogenicity and could serve as a novel potential vaccine platform for MERS in dromedary camels and human.
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION